Actively Recruiting
Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens
Led by Brigham and Women's Hospital · Updated on 2026-03-05
160
Participants Needed
1
Research Sites
47 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying a new standardized technique to improve lymph node dissection in patients with clinical stage I or II non-small cell lung cancer (NSCLC) who undergo upfront lung surgery. The goal is to better retrieve lymph nodes from lung resection specimens, which may enhance cancer staging accuracy and help identify more patients who could benefit from additional treatments after surgery. Accurate lymph node assessment is critical because it affects prognosis and treatment decisions for lung cancer patients. The study compares a systematic lymph node dissection method performed on fresh and fixed lung cancer lobectomy specimens. This involves a careful, standardized dissection of the lobectomy sample starting at the lung hilum and extending to the periphery, focusing on areas where lymph nodes cluster. The technique is carried out by the surgeon and/or pathology team following a specific protocol to maximize lymph node removal and improve staging accuracy. Participants include those undergoing lobectomy with peripheral lung nodules and no metastasis. Participants will be monitored shortly after surgery to measure the number of lymph nodes sampled and the nodal upstage rate within two weeks. Longer-term outcomes include recurrence-free survival measured over three years. Data collection involves detailed pathological examination of the surgical specimens to assess lymph nodes. The study aims to improve lung cancer staging and guide therapy decisions, with the total follow-up extending to at least three years after surgery.
CONDITIONS
Brief Title
Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Subjects with a lung nodule or mass who are eligible to undergo a lobectomy.
- Subjects without any metastasis present.
- Subjects who have peripheral lung nodule location.
- Subjects must be 18 years of age or older.
You will not qualify if you...
- Subjects who received preoperative chemotherapy or radiotherapy.
- Subjects who have a lung nodule located in a central location. Central tumors are defined by those infiltrating the lobar airway.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 2 weeks
Participants undergo lung specimen lymph node dissection performed by the thoracic surgeon and/or pathology team to maximize lymph node retrieval and improve cancer staging accuracy.
1 surgical visit and lymph node dissection procedure
Duration - 3 years
Participants are monitored for recurrence-free survival and oncologic outcomes following lymph node dissection and lung resection.
Periodic follow-up visits over 3 years
Trial Site Locations
Total: 1 location
1
Brigham and Womens Hospital
Boston, Massachusetts, United States, 02115
Actively Recruiting
Research Team
P
Paula Ugalde Figueroa, M.D.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here